KR20130130580A - Composition for preventing or treating gout containing mixed medicinal herbs extracts and method of preparing the extracts - Google Patents
Composition for preventing or treating gout containing mixed medicinal herbs extracts and method of preparing the extracts Download PDFInfo
- Publication number
- KR20130130580A KR20130130580A KR1020120054499A KR20120054499A KR20130130580A KR 20130130580 A KR20130130580 A KR 20130130580A KR 1020120054499 A KR1020120054499 A KR 1020120054499A KR 20120054499 A KR20120054499 A KR 20120054499A KR 20130130580 A KR20130130580 A KR 20130130580A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- preventing
- mixed medicinal
- weight
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 65
- 201000005569 Gout Diseases 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 18
- 235000008216 herbs Nutrition 0.000 title abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 31
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- 239000000706 filtrate Substances 0.000 claims abstract description 14
- 238000001914 filtration Methods 0.000 claims abstract description 9
- 238000007731 hot pressing Methods 0.000 claims abstract description 6
- 238000003303 reheating Methods 0.000 claims abstract description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 31
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 31
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 31
- 229940010454 licorice Drugs 0.000 claims description 31
- 241000736199 Paeonia Species 0.000 claims description 28
- 241000202807 Glycyrrhiza Species 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 4
- 239000012676 herbal extract Substances 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 19
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 18
- 229940116269 uric acid Drugs 0.000 abstract description 18
- 240000006274 Actinidia polygama Species 0.000 abstract description 5
- 235000016413 Actinidia polygama Nutrition 0.000 abstract description 5
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract 3
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract 3
- 241001106477 Paeoniaceae Species 0.000 abstract 3
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 10
- 244000303040 Glycyrrhiza glabra Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- -1 mucus Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 201000001431 Hyperuricemia Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000219066 Actinidiaceae Species 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 244000236655 Diospyros kaki Species 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 208000009911 Urinary Calculi Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000000729 antidote Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000011309 nasal bleeding Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 208000008281 urolithiasis Diseases 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- IAPCTXZQXAVYNG-UHFFFAOYSA-M Potassium 2,6-dihydroxytriazinecarboxylate Chemical compound [K+].[O-]C(=O)C1=NC(=O)NC(=O)N1 IAPCTXZQXAVYNG-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물에 관한 것으로서, 보다 구체적으로는 개다래, 감초 및 작약의 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물 및 그 제조 방법에 관한 것이다.The present invention relates to a composition for preventing or treating gout comprising a mixed medicinal herb extract as an active ingredient, and more particularly, a composition for preventing or treating gout comprising a mixed medicinal extract of Cauliflower, licorice and peony as an active ingredient and its preparation It is about a method.
통풍(Gout)은 혈액 내에 요산(음식을 통해 섭취되는 퓨린(purine)이라는 물질을 인체가 대사하고 남은 산물)의 농도가 높아지면서 요산염(요산이 혈액, 체액, 관절액 내에서는 요산염의 형태로 존재함) 결정이 관절의 연골, 힘줄, 주위 조직에 침착되는 대사성 질환이다. 혈액 내 요산 농도가 증가하는 원인은 크게 요산이 과잉 생산되거나 요산 배설이 감소되는 것을 들 수 있는데, 각각의 경우에 대하여 다양한 원인 질환이 있을 수 있으며, 그 원인을 밝힐 수 없는 경우도 있다.
Gout is an increase in the concentration of uric acid (a product of the body's metabolism of purine, which is ingested through food) in the blood, resulting in the addition of uric acid (ureate in the form of uric acid in the blood, body fluids, and joint fluids). Present) is a metabolic disease in which crystals are deposited on cartilage, tendons and surrounding tissues of joints. The cause of the increase in the concentration of uric acid in the blood may be a large amount of excessive production of uric acid or reduced uric acid excretion, there may be a variety of causal diseases for each case, the cause may not be identified.
이와 같은 통풍은, 1) 무증상 고요산혈증, 2) 급성 통풍성 관절염, 3) 간헐기 통풍, 4) 만성 결절성 통풍의 전형적인 4단계의 증상을 나타내게 되는데, 보다 구체적으로 무증상 고요산혈증 단계에서는 혈청 요산의 농도는 증가되어 있지만 관절염 증상, 통풍 결절, 요산 콩팥돌증 등의 증상은 아직 나타나지 않는다. 급성 통풍성 관절염 단계에서는 대개 최소한 20년 동안 지속되는 고요산혈증이 지난 후 첫 번째 통풍발작이 나타나거나 콩팥돌증이 발생하며, 간헐기 통풍 단계에서는 대부분의 환자들이 6개월에서 2년 사이에 두 번째 발작을 경험하게 되고, 만성 결절성 통풍 단계에서는 통풍결절 형성과 통풍발작이 고요산혈증의 정도와 기간에 비례하여 증가하게 된다.
These gouts present four typical symptoms of: 1) asymptomatic hyperuricemia, 2) acute gouty arthritis, 3) intermittent gout, and 4) chronic nodular gout. More specifically, the level of serum uric acid in asymptomatic hyperuricemia , But symptoms such as arthritis, gout nodules and uric acid kidney disease do not appear yet. In the stage of acute gouty arthritis, the first gout or kidney disease occurs after hyperuricemia, which usually lasts for at least 20 years, and in the intermittent gout phase, most patients develop a second attack between six months and two years. In chronic nodular gout stages, gout nodule formation and gout attacks increase in proportion to the degree and duration of hyperuricemia.
현재, 통풍을 예방 또는 치료하기 위해서는 체중 조절, 절주, 과식 자제 등의 생활 습관 개선과 함께 알로퓨리놀(allopurinol), 프로베네시드(probenecid) 등의 요산배설촉진제가 주로 사용되고 있다. 하지만 이러한 약물들은 피부발진이나 위장장애 또는 간과 신장의 손상, 혈구 수의 변화와 같은 약물에 대한 알레르기성 반응 등의 부작용이 나타날 수 있다. 따라서 최근에는 천연 추출물을 이용하여 통풍을 예방 또는 치료하는 치료제에 대한 관심의 증가와 함께 다양한 연구가 진행되고 있다(특허공개번호 제10-2010-0122309호 참조).
Currently, uric acid excretion accelerators such as allopurinol, probenecid, and the like are mainly used to improve or prevent gout and to improve lifestyles such as weight control, sobriety, and overeating. However, these drugs can cause side effects such as skin rashes, gastrointestinal disorders, allergic reactions to drugs such as liver and kidney damage, and changes in blood counts. Therefore, recently, various studies have been conducted with increasing interest in therapeutic agents for preventing or treating gout using natural extracts (see Patent Publication No. 10-2010-0122309).
한편, 개다래(Actinidia polygama)는 다래나무(미후리)과(Actinidiaceae)에 속한 낙엽 덩굴성 식물인 개다래나무의 과실로서, 자당, 점액질, 전분, 단백질, 탄닌, 유기산, 비타민 C, 비타민 A, 비타민 P 등이 함유되어 있으며, 지갈(止渴), 해번열(解煩熱)과 비뇨기결석(泌尿器結石) 등의 치료에 사용된다고 알려져 있다.
On the other hand, Actinidia polygama is a fruit of the deciduous vine, a deciduous vine plant belonging to the genus Actinidiaceae, sucrose, mucus, starch, protein, tannin, organic acid, vitamin C, vitamin A, vitamin P is contained, and it is known to be used for the treatment of jigal (,), sunburn fever (解 煩熱) and urinary stones (泌尿 器 結石).
감초는 콩(Leguminosae)과에 속하는 다년생 초본으로서, 감미질인 글리시리진, 플라보노이드의 일종인 리키리틴, 서당, 포도당, 만니톨, 아스파라긴 등이 함유되어 있으며, 이러한 감초는 여러 가지 질병에 대한 치료효과와 항균작용 및 우수한 항산화능이 알려져 있어 유옹, 습양, 생창 등에 효과가 있고, 해독제, 염증제로도 사용되고 있다고 알려져 있다.
Licorice is a perennial herb belonging to the legume (Leguminosae) family, and contains sweeteners such as glycyrigin and flavonoids such as lycuritin, sucrose, glucose, mannitol, and asparagine. And it is known that the excellent antioxidant capacity is effective in oozing, wetting, growth and the like, and is also used as an antidote and an inflammatory agent.
작약은 함박꽃이라고도 하며 미나리아재비(Ranunculaceae)과에 속하는 다년생 숙근 초본으로서, 페오니플로린(paeoniflorin)과 알비플로린(albiflorin)을 포함한 모토터핀 글루코사이드(monoterpene glucoside) 화합물과 수종의 페놀릭 화합물(pheonolic compound)이 함유되어 있으며, 염증, 진통 및 진경(鎭痙)의 목적으로 주로 무월경의 조절, 외상치료, 비출혈, 염증, 종기 및 상처 치료, 가슴과 늑골부위의 통증완화 등의 치료에 사용된다고 알려져 있다.
Peony is a perennial herbaceous herb that belongs to the Ranunculaceae family, which is also known as a persimmon flower. It is known to be used for the treatment of amenorrhea, trauma, nasal bleeding, inflammation, boils and wounds, and pain relief of the chest and ribs for the purpose of inflammation, analgesic and dysmenorrhea. .
이상에서 살펴본 결과, 통풍을 예방 또는 치료하는 조성물의 개발이 중요한 과제로 되고 있고, 개다래, 감초 및 작약을 이러한 치료제로 사용하는 것이 관심의 대상이 되고 있다.As a result of the above, the development of a composition for preventing or treating gout has become an important problem, and the use of cabbage, licorice and peony as such therapeutic agents is of interest.
본 발명은 기존에 제안된 방법들의 상기와 같은 문제점들을 해결하기 위해 제안된 것으로서, 개다래, 감초 및 작약의 혼합 약재 추출물을 포함함으로써 혈중 요산의 농도를 저하시켜 통풍을 예방 또는 치료할 수 있는, 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물 및 그 제조 방법을 제공하는 것을 그 목적으로 한다.The present invention has been proposed to solve the above problems of the conventionally proposed methods, by including a mixed medicinal herb extract of Cabbage, Licorice and Peony can lower or lower the concentration of uric acid in the blood to prevent or treat gout It is an object of the present invention to provide a composition for preventing or treating gout comprising the extract as an active ingredient and a method for producing the same.
상기한 목적을 달성하기 위한 본 발명의 특징에 따른 통풍 예방 또는 치료용 조성물은,Composition for preventing or treating gout according to the characteristics of the present invention for achieving the above object,
개다래, 감초 및 작약의 혼합 약재 추출물을 유효성분으로 포함하는 것을 그 구성상의 특징으로 한다.
Characterized by its constituent features including an extract of the mixed medicinal herb, licorice and peony as an active ingredient.
바람직하게는, 상기 혼합 약재 추출물은,Preferably, the mixed medicinal extract,
상기 개다래, 감초 및 작약의 총 중량대비 5~15배 중량의 물을 사용하여 추출할 수 있다.
It can be extracted using 5 to 15 times the weight of water compared to the total weight of the leek, licorice and peony.
바람직하게는, 상기 혼합 약재 추출물은,Preferably, the mixed medicinal extract,
개다래 1~5중량%, 감초 1~5중량% 및 작약 1~5중량%를 포함할 수 있다.
It may include 1-5% by weight, 1-5% by weight licorice and 1-5% by weight peony.
상기한 목적을 달성하기 위한 본 발명의 특징에 따른 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물 제조 방법은,Method for producing a composition for preventing or treating gout comprising a mixed medicinal extract according to the characteristics of the present invention for achieving the above object as an active ingredient,
(1) 일정크기의 압력솥에 개다래 1~5중량%, 감초 1~5중량%, 작약 1~5중량% 및 물 90~95중량%를 투입하고 고온 가압하여 열수 추출액을 수득하는 단계;(1) adding 1-5% by weight, 1-5% by weight licorice, 1-5% by weight peony and 90-95% by weight water to a pressure cooker of a predetermined size to obtain a hot water extract by hot pressing;
(2) 상기 압력솥 내부에 생성된 압축공기를 배출하는 단계; 및(2) discharging the compressed air generated inside the pressure cooker; And
(3) 상기 열수 추출액을 여과하여 여액을 회수하는 단계를 포함하는 것을 그 구성상의 특징으로 한다.
(3) filtering the hot water extract and recovering the filtrate.
바람직하게는,Preferably,
(4) 상기 여액을 재가열하는 단계를 더 포함할 수 있다.
(4) The method may further include reheating the filtrate.
바람직하게는, 상기 단계 (1)은,Preferably, the step (1)
2.5기압, 115~125℃에서 2.5~3시간 동안 수행될 수 있다.2.5 atm, 115 to 125 ℃ can be carried out for 2.5 to 3 hours.
본 발명에서 제안하고 있는 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물 및 그 제조 방법에 따르면, 개다래, 감초 및 작약의 혼합 약재 추출물을 포함함으로써 혈중 요산의 농도를 저하시켜 통풍을 예방 또는 치료할 수 있다.According to the composition for preventing gout or treatment comprising a mixed medicinal herb extract proposed in the present invention as an active ingredient and a method for preparing the same, by preventing the gout by lowering the concentration of uric acid in the blood by including a mixed medicinal extract of Caesar, Licorice and Peony Or can be treated.
도 1은 본 발명의 일실시예에 따른 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물 제조 방법의 공정도를 도시한 도면.
도 2는 본 발명의 일실시예에 따른 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물의 혈중 요산 농도 변화 실험 결과를 나타낸 도면.1 is a view showing a process of manufacturing a composition for preventing or treating gout containing a mixed medicinal herb extract according to an embodiment of the present invention as an active ingredient.
Figure 2 is a view showing the results of experiments to change the blood uric acid concentration in the composition for preventing or treating gout containing the mixed medicinal herb extract according to an embodiment of the present invention.
이하, 첨부된 도면을 참조하여 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 본 발명을 용이하게 실시할 수 있도록 바람직한 실시예를 상세히 설명한다. 다만, 본 발명의 바람직한 실시예를 상세하게 설명함에 있어, 관련된 공지 기능 또는 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우에는 그 상세한 설명을 생략한다. 또한, 유사한 기능 및 작용을 하는 부분에 대해서는 도면 전체에 걸쳐 동일한 부호를 사용한다.
Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings, in order that those skilled in the art can easily carry out the present invention. In the following detailed description of the preferred embodiments of the present invention, a detailed description of known functions and configurations incorporated herein will be omitted when it may make the subject matter of the present invention rather unclear. In the drawings, like reference numerals are used throughout the drawings.
덧붙여, 명세서 전체에서, 어떤 부분이 다른 부분과 ‘연결’ 되어 있다고 할 때, 이는 ‘직접적으로 연결’ 되어 있는 경우뿐만 아니라, 그 중간에 다른 소자를 사이에 두고 ‘간접적으로 연결’ 되어 있는 경우도 포함한다. 또한, 어떤 구성요소를 ‘포함’ 한다는 것은, 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성요소를 더 포함할 수 있다는 것을 의미한다.
In addition, in the entire specification, when a part is referred to as being 'connected' to another part, it may be referred to as 'indirectly connected' not only with 'directly connected' . In addition, the term 'comprising' of an element means that the element may further include other elements, not to exclude other elements unless specifically stated otherwise.
본 명세서에 있어서, "유효성분"이라 함은 내재된 약리작용에 의해 그 조성물의 효능효과를 직접 또는 간접적으로 발현한다고 기대되는 물질 또는 물질군(약리학적 활성성분 등이 밝혀지지 않은 생약 등을 포함한다)으로서 주성분을 포함하는 것을 의미한다.
In the present specification, the term "active ingredient" includes a substance or a group of substances (a pharmacologically active ingredient or the like which is expected to express the efficacy effect of the composition directly or indirectly by inherent pharmacological action). Means a main component).
개다래(Actinidia polygama)는 다래나무(미후리)과 (Actinidiaceae)에 속한 낙엽 덩굴성 식물인 개다래나무의 과실로서, 자당, 점액질, 전분, 단백질, 탄닌, 유기산, 비타민 C, 비타민 A, 비타민 P 등이 함유되어 있으며, 지갈(止渴), 해번열(解煩熱)과 비뇨기결석(泌尿器結石) 등의 치료에 사용된다고 알려져 있다.
Actinidia polygama is a fruit of the deciduous vine, a deciduous vine plant belonging to the genus A. quince and Actinidiaceae. Sucrose, mucosa, starch, protein, tannin, organic acid, vitamin C, vitamin A, and vitamin P. It is known to be used for the treatment of jigal (,), sunburn fever (解 煩熱) and urinary stones (泌尿 器 結石).
감초는 콩(Leguminosae)과에 속하는 다년생 초본으로서, 감미질인 글리시리진, 플라보노이드의 일종인 리키리틴, 서당, 포도당, 만니톨, 아스파라긴 등이 함유되어 있으며, 이러한 감초는 여러 가지 질병에 대한 치료효과와 항균작용 및 우수한 항산화능이 알려져 있어 유옹, 습양, 생창 등에 효과가 있고, 해독제, 염증제로도 사용되고 있다고 알려져 있다.
Licorice is a perennial herb belonging to the legume (Leguminosae) family, and contains sweeteners such as glycyrigin and flavonoids such as lycuritin, sucrose, glucose, mannitol, and asparagine. And it is known that the excellent antioxidant capacity is effective in oozing, wetting, growth and the like, and is also used as an antidote and an inflammatory agent.
작약은 함박꽃이라고도 하며 미나리아재비(Ranunculaceae)과에 속하는 다년생 숙근 초본으로서, 페오니플로린(paeoniflorin)과 알비플로린(albiflorin)을 포함한 모토터핀 글루코사이드(monoterpene glucoside) 화합물과 수종의 페놀릭 화합물(pheonolic compound)이 함유되어 있으며, 염증, 진통 및 진경(鎭痙)의 목적으로 주로 무월경의 조절, 외상치료, 비출혈, 염증, 종기 및 상처 치료, 가슴과 늑골부위의 통증완화 등의 치료에 사용된다고 알려져 있다.
Peony is a perennial herbaceous herb that belongs to the Ranunculaceae family, which is also known as a persimmon flower. It is known to be used for the treatment of amenorrhea, trauma, nasal bleeding, inflammation, boils and wounds, and pain relief of the chest and ribs for the purpose of inflammation, analgesic and dysmenorrhea. .
본 발명자들은 이러한 개다래, 감초 및 작약의 혼합 약재 추출물이 혈중 요산의 농도를 저하시켜 통풍의 예방 또는 치료에 우수한 효과를 나타내는 것을 실험적으로 확인하고, 또한 급성 독성 실험을 통하여 개다래, 감초 및 작약의 혼합 약재 추출물이 인체에 매우 안전한 약물임을 밝혀서 본 발명을 완성하였다.
The present inventors experimentally confirmed that the mixed medicinal herb extract of Licorice, Licorice and Peony lowers the concentration of uric acid in the blood and shows an excellent effect on the prevention or treatment of gout. Medicinal extracts have been found to be a very safe drug for the human body to complete the present invention.
즉, 본 발명의 일실시예에 따른 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물은 개다래, 감초 및 작약의 혼합 약재 추출물을 유효성분으로 포함하는 것을 특징으로 한다. 이러한 혼합 약재 추출물은 물 특히 정제수를 용매로 사용하여 추출할 수 있으며, 보다 구체적으로는 개다래, 감초 및 작약의 총 중량대비 5~15배 중량의 물을 사용하여 추출하는 것이 바람직하다. 또한, 본 발명의 일실시예에 따른 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물에 포함되는 혼합 약재 추출물은 개다래 1~5중량%, 감초 1~5중량% 및 작약 1~5중량%를 포함하는 것이 바람직하다.
That is, the composition for preventing gout or treatment comprising a mixed medicinal herb extract according to an embodiment of the present invention as an active ingredient is characterized in that it comprises a mixed medicinal herb, licorice and peony as an active ingredient. The mixed medicinal herb extract can be extracted using water, in particular, purified water as a solvent, and more specifically, it is preferably extracted using 5 to 15 times the weight of water compared to the total weight of seaweed, licorice and peony. In addition, the mixed medicinal herb extract contained in the composition for preventing or treating gout containing the mixed medicinal herb extract according to an embodiment of the present invention is 1-5% by weight, licorice 1-5% by weight and peony 1-5 It is preferable to include the weight percent.
한편, 본 발명의 일실시예에 따른 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물에 포함되는 개다래, 감초 및 작약은 건조 상태 또는 자연 그대로 추출하여 이용할 수 있으며, 추출 효율을 높이기 위해, 분절 또는 분쇄시켜 이용할 수도 있다.
On the other hand, the wormwood, licorice and peony contained in the composition for preventing gout or treatment comprising the mixed medicinal extract as an active ingredient according to an embodiment of the present invention can be used to extract the dry state or as it is natural, in order to increase the extraction efficiency It may also be used by crushing or grinding.
이하에서는, 본 발명의 일실시예에 따른 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물의 제조 방법을 상세히 설명하도록 한다.
Hereinafter, a method for preparing a composition for preventing or treating gout comprising a mixed medicinal extract according to an embodiment of the present invention as an active ingredient.
도 1은 본 발명의 일실시예에 따른 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물 제조 방법의 공정도를 도시한 도면이다. 도 1에 도시된 바와 같이, 본 발명의 일실시예에 따른 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물 제조 방법은, 일정크기의 압력솥에 개다래 1~5중량%, 감초 1~5중량%, 작약 1~5중량% 및 물 90~95중량%를 투입하고 고온 가압하여 열수 추출액을 수득하는 단계(S100), 압력솥 내부에 생성된 압축공기를 배출하는 단계(S200) 및 열수 추출액을 여과하여 여액을 회수하는 단계(S300)를 포함하여 구성될 수 있고, 여액을 재가열하는 단계(S400)를 더 포함할 수 있다.
1 is a view showing a process diagram of a method for preparing a composition for preventing or treating gout containing the mixed medicinal extract as an active ingredient according to an embodiment of the present invention. As shown in Figure 1, the method for producing a composition for preventing or treating gout comprising a mixed medicinal herb extract according to an embodiment of the present invention as an active ingredient, 1 ~ 5% by weight, Licorice 1 ~ 5% by weight, peony 1-5% by weight and 90-95% by weight of water to obtain a hot water extract by hot pressing (S100), discharging the compressed air generated in the pressure cooker (S200) and hot water extract It may be configured to include the step of recovering the filtrate by filtering (S300), it may further comprise the step of reheating the filtrate (S400).
단계 S100에서는, 압력솥에 개다래, 감초, 작약 및 물을 투입하고 고온 가압하여 혼합 약재의 열수 추출액을 수득한다. 보다 구체적으로, 개다래 1~5중량%, 감초 1~5중량%, 작약 1~5중량% 및 물 90~95중량%를 투입하고, 압력솥의 내부를 2.5기압, 115~125℃의 온도범위를 유지하면서 2.5~3시간 동안 고온 가압하여 혼합 약재의 열수 추출액을 수득하는 것이 바람직하다.
In step S100, we put a litter, licorice, peony and water into a pressure cooker and pressurized at high temperature to obtain a hot water extract of the mixed medicine. More specifically, 1 to 5% by weight, licorice 1-5%, peony 1-5% and water 90-95% by weight, the inside of the pressure cooker at 2.5 atmospheres, 115-125 ℃ temperature range It is preferable to obtain hot water extract of the mixed medicine by hot pressing for 2.5 to 3 hours while maintaining.
단계 S200에서는, 단계 S100을 수행하는 과정에서 압력솥 내부에 생성된 압축공기를 배출하며, 보다 구체적으로는 단계 S100이 종료된 후 1~2시간 후에 압축공기를 배출하는 것이 바람직하다.
In step S200, the compressed air generated inside the pressure cooker in the process of performing step S100 is discharged, and more specifically, it is preferable to discharge the compressed air 1 to 2 hours after the step S100 is finished.
단계 S300에서는, 단계 S100에 의해 수득된 혼합 약재의 열수 추출액을 여과하여 여액을 회수한다. 즉, 착즙기나 압착여과기 등을 이용하여 열수 추출액을 여과함으로써 추출액에 포함되어 있던 개다래, 감초 및 작약의 고형분을 제거한다.
In step S300, the filtrate is recovered by filtering the hot water extract of the mixed medicine obtained in step S100. That is, the hot water extract is filtered using a juicer, a squeezed filter, or the like to remove the solids of the cauliflower, licorice and peony contained in the extract.
단계 S400에서는 단계 S300에 의해 여과된 여액을 재가열한다. 즉, 단계 S300에 의해 여과를 하여도 여전히 개다래, 감초 및 작약의 작용효과를 방해하는 기타 불순물들이 함유되어 있을 수 있기 때문에, 이를 위해, 단계 S400에서는 단계 S300에 의해 여과된 여액을 재가열함으로써 개다래, 감초 및 작약의 작용효과를 방해하는 기타 불순물들을 제거한다.
In step S400, the filtrate filtered by step S300 is reheated. That is, even though the filtration in step S300 may still contain the algae, licorice and other impurities that interfere with the effect of the peony, for this purpose, in step S400, by heating the filtrate filtered in step S300 Eliminate licorice and other impurities that interfere with the effectiveness of the peony.
한편, 상기와 같은 제조 방법에 의해 제조된 본 발명의 일실시예에 따른 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물은 적정한 1회 복용량 씩 개별 포장되거나 용기에 일괄 포장될 수 있다.
Meanwhile, the composition for preventing or treating gout containing the mixed medicinal herb extract according to one embodiment of the present invention prepared as the active ingredient as an active ingredient may be individually packaged by an appropriate dose or packaged in a container. .
뿐만 아니라, 본 발명에 따른 혼합 약재 추출물을 포함하는 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.
In addition, the composition comprising the mixed medicinal extract according to the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명에 따른 혼합 약재 추출물을 포함하는 약학 조성물의 약제학적 투여 형태는 이들의 약제학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 다른 약제학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다.
The pharmaceutical dosage forms of the pharmaceutical compositions comprising the mixed medicinal extracts according to the present invention may be used in the form of their pharmaceutically acceptable salts, and may also be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection. have.
본 발명에 따른 혼합 약재 추출물을 포함하는 약학 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 본 발명에 따른 혼합 약재 추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등이 있으며, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제할 수 있다. 경구투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 있으며, 이러한 고형 제제는 혼합 약재 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 혼합하여 조제할 수 있다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 있는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등을 혼합하여 조제할 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제 등이 있으며, 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.
The pharmaceutical composition comprising the mixed medicinal compound extract according to the present invention may be formulated into oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations, suppositories and sterilized injection solutions Can be used. Examples of carriers, excipients and diluents that can be included in the composition including the mixed medicinal extract according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin , Calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. A diluent or excipient such as a commonly used filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant may be used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations may contain at least one excipient such as starch, calcium carbonate and sucrose in a mixed medicinal extract. ) Or lactose, gelatin and the like can be mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups. In addition to the commonly used simple diluents, water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be prepared. Can be. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories, and the like, and non-aqueous solvents and suspensions include vegetable oils such as propylene glycol, polyethylene glycol and olive oil. Injectable esters such as ethyl oleate, and the like can be used.
본 발명에 따른 혼합 약재 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 하지만, 바람직하게는 본 발명에 따른 혼합 약재 추출물을 1일 0.001~100㎎/체중㎏으로, 더욱 바람직하게는 0.01~40㎎/체중㎏으로 투여한다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.
The preferred dosage of the mixed medicinal extract according to the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, preferably the mixed medicinal extract according to the present invention is administered at 0.001-100 mg / kg body weight per day, more preferably 0.01-40 mg / kg body weight. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.
본 발명에 따른 혼합 약재 추출물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여방법에는 제한이 없으며, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관(intracerbroventricular) 주사에 의해 투여될 수 있다.
The mixed medicinal extract according to the present invention can be administered to mammals such as rats, mice, livestock, and humans in various routes. The method of administration is not limited and may be administered, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine epidural or cerebrovascular (intracerbroventricular) injection.
본 발명은 이하의 실시예에 의하여 더욱 상세히 설명되나, 본 발명이 이하의 실시예에 의해 어떤 식으로든 제한되는 것은 아니다.
The present invention is explained in more detail by the following examples, but the present invention is not limited in any way by the following examples.
통풍 예방 또는 치료용 조성물 제조Manufacture of compositions for the prevention or treatment of gout
개다래 열매 300g, 감초 200g, 작약 500g 및 물 14L를 압력솥에 투입하고, 3시간 동안 2.5기압 및 120℃로 고온 가압하면서 열수 추출물을 수득하였다. 2시간 후 압축공기를 배출하고, 여과 압축기를 이용하여 고형분을 제거한 후, 90~100℃로 재가열하여 조성물을 제조하였다.
300 g of Licorice fruit, 200 g of licorice, 500 g of peony, and 14 L of water were put in a pressure cooker, and a hot water extract was obtained while pressurizing at 2.5 atm and 120 ° C. for 3 hours. After 2 hours, the compressed air was discharged, the solids were removed using a filtration compressor, and the composition was reheated to 90 to 100 ° C.
이하에서는, 본 발명의 효과를 실험예를 통하여 더욱 상세하게 설명하지만, 본 발명의 권리범위가 하기 실험예에 의해 한정되는 것은 아니다.
Hereinafter, the effects of the present invention will be described in more detail through experimental examples, but the scope of the present invention is not limited by the following experimental examples.
[실험예 1][Experimental Example 1]
혈중 요산 농도 변화 실험Blood uric acid concentration change experiment
본 발명에 따른 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물에 의한 항통풍 효과를 확인하기 위하여 하기와 같이 동물 실험을 진행하였다.
In order to confirm the anti-gout effect by the composition for preventing or treating gout containing the mixed medicinal extract according to the present invention as an active ingredient, the animal experiment was carried out as follows.
1. 실험대상 및 기간1. Subject and Period
본 실험의 대상은 100~200g의 6주령 실험용 랫(SD 랫)을 대상으로 하였고, 실험기간은 7일로 하였다.
The subjects of this experiment were 100-200 g 6-week-old rats (SD rats), and the experimental period was 7 days.
2. 실험방법2. Experimental method
실험용 랫(SD 랫)을 5마리씩 각각 하나의 실험군과 대조군으로 나눈 후, 실험군에는 실시예 1에서 제조된 조성물 100㎎/㎏을 일주일 동안 경구투여하였고, 대조군에는 생리식염수를 투여하였다. 마지막 투여 1시간 전에 혈중요산증을 유발하기 위하여 포타슘 옥소네이트 280㎎/㎏을 복강 내 주사하였고, 투여와 주사가 끝난 동물은 심장 채혈법으로 희생시켜 혈액을 수집한 후 혈장을 분리하여 혈중 요산의 함량을 측정하였다.
Experimental rats (SD rats) were divided into five test dogs and one control group, respectively, and the experimental group was orally administered with 100 mg / kg of the composition prepared in Example 1 for one week, and the control group was administered saline. One hour before the last dose, 280 mg / kg of potassium oxonate was injected intraperitoneally to induce blood uric acidosis. After the administration and injection, the animals were sacrificed by cardiac collection to collect blood, and then plasma was separated. The content was measured.
3. 결과3. Results
투여와 주사가 끝난 동물에서 수집한 혈액에서 혈중 요산을 측정한 결과를 도 2에 나타내었다. 도 2에 나타낸 바와 같이, 실험군에서는 대조군에 비하여 혈중 요산의 함량에 있어 유의한 차이를 나타내었다. 즉, 본 발명에 따른 조성물을 투여한 실험군은 대조군보다 55% 이상의 혈중 요산 저하 효과를 나타내었다. 따라서 본 발명에 따른 개다래, 감초 및 작약의 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물은 통풍을 예방 또는 치료하는데 매우 효과적임을 확인하였다.
The results of measuring blood uric acid in the blood collected from the animals after the administration and injection are shown in FIG. 2. As shown in Figure 2, the experimental group showed a significant difference in the content of uric acid in the blood compared to the control group. That is, the experimental group administered the composition according to the present invention showed a blood uric acid lowering effect of 55% or more than the control group. Therefore, it was confirmed that the composition for preventing or treating gout containing mixed medicinal herb extract of Lichen, Licorice and Peony according to the present invention as an active ingredient is very effective in preventing or treating gout.
[실험예 2][Experimental Example 2]
독성실험Toxicity Test
실험용 랫(SD 랫) 3마리에 실시예 1에서 제조된 통풍 예방 또는 치료용 조성물을 각각 20㎎/㎏, 10㎎/㎏, 1㎎/㎏씩 주입하고 7일 동안 관찰하여도 독성효과가 발견되지 않았고 사망하는 것이 없었다. 따라서 본 발명에 따른 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물은 안전한 약물임을 확인할 수 있었다.
Toxic effect was found even after 7 days of injecting 20 g / kg, 10 mg / kg and 1 mg / kg of the gout preventing or treating composition prepared in Example 1 into three experimental rats (SD rats). There was no death. Therefore, the composition for preventing or treating gout containing the mixed medicinal extract according to the present invention as an active ingredient was confirmed to be a safe drug.
이상 설명한 본 발명은 본 발명이 속한 기술분야에서 통상의 지식을 가진 자에 의하여 다양한 변형이나 응용이 가능하며, 본 발명에 따른 기술적 사상의 범위는 아래의 특허청구범위에 의하여 정해져야 할 것이다.The present invention may be embodied in many other specific forms without departing from the spirit or essential characteristics of the invention.
S100: 일정크기의 압력솥에 개다래 1~5중량%, 감초 1~5중량%, 작약 1~5중량% 및 물 90~95중량%를 투입하고 고온 가압하여 열수 추출액을 수득하는 단계
S200: 압력솥 내부에 생성된 압축공기를 배출하는 단계
S300: 열수 추출액을 여과하여 여액을 회수하는 단계
S400: 여액을 재가열하는 단계S100: step 1 to 5% by weight, licorice 1 to 5% by weight, peony 1 to 5% by weight and water 90 to 95% by weight in a pressure cooker of a certain size to obtain a hot water extract by high pressure
S200: discharging the compressed air generated inside the pressure cooker
S300: filtering the hot water extract to recover the filtrate
S400: step of reheating the filtrate
Claims (6)
Gout prevention, a composition for preventing or treating gout comprising a mixed herbal extract of licorice and peony as an active ingredient.
상기 개다래, 감초 및 작약의 총 중량대비 5~15배 중량의 물을 사용하여 추출하는 것을 특징으로 하는, 통풍 예방 또는 치료용 조성물.
The method of claim 1, wherein the mixed medicinal extract,
Characterized in that the extract using water of 5 to 15 times the weight of the total weight of licorice, licorice and peony, composition for preventing or treating gout.
개다래 1~5중량%, 감초 1~5중량% 및 작약 1~5중량%를 포함하는 것을 특징으로 하는, 통풍 예방 또는 치료용 조성물.
The method of claim 1, wherein the mixed medicinal extract,
1-5% by weight, licorice 1-5% by weight and peony 1-5% by weight, characterized in that the composition for preventing or treating gout.
(2) 상기 압력솥 내부에 생성된 압축공기를 배출하는 단계; 및
(3) 상기 열수 추출액을 여과하여 여액을 회수하는 단계를 포함하는 것을 특징으로 하는, 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물 제조 방법.
(1) adding 1-5% by weight, 1-5% by weight licorice, 1-5% by weight peony and 90-95% by weight water to a pressure cooker of a predetermined size to obtain a hot water extract by hot pressing;
(2) discharging the compressed air generated inside the pressure cooker; And
(3) characterized in that it comprises the step of recovering the filtrate by filtering the hot water extract, gout prevention or treatment composition production method comprising a mixed medicinal extract as an active ingredient.
(4) 상기 여액을 재가열하는 단계를 더 포함하는 것을 특징으로 하는, 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물 제조 방법.
5. The method of claim 4,
(4) characterized in that it further comprises the step of reheating the filtrate, gout prevention or treatment composition production method comprising a mixed medicinal herb extract as an active ingredient.
2.5기압, 115~125℃에서 2.5~3시간 동안 수행되는 것을 특징으로 하는, 혼합 약재 추출물을 유효성분으로 포함하는 통풍 예방 또는 치료용 조성물 제조 방법.4. The method of claim 3, wherein step (1)
Method for producing a composition for preventing or treating gout comprising a mixed medicinal herb extract as an active ingredient, characterized in that it is carried out at 2.5 atm, 115 to 125 ℃ for 2.5 to 3 hours.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120054499A KR20130130580A (en) | 2012-05-22 | 2012-05-22 | Composition for preventing or treating gout containing mixed medicinal herbs extracts and method of preparing the extracts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120054499A KR20130130580A (en) | 2012-05-22 | 2012-05-22 | Composition for preventing or treating gout containing mixed medicinal herbs extracts and method of preparing the extracts |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20130130580A true KR20130130580A (en) | 2013-12-02 |
Family
ID=49980224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120054499A KR20130130580A (en) | 2012-05-22 | 2012-05-22 | Composition for preventing or treating gout containing mixed medicinal herbs extracts and method of preparing the extracts |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20130130580A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104800695A (en) * | 2015-05-11 | 2015-07-29 | 广西梧州茂圣茶业有限公司 | Liupu tea-containing composition with function of reducing blood uric acid |
KR101715520B1 (en) | 2015-11-12 | 2017-03-13 | 한림대학교 산학협력단 | The pharmaceutical compositions for the treatment of gout |
WO2018079985A1 (en) | 2016-10-25 | 2018-05-03 | 엘지전자 주식회사 | Vacuum cleaner and control method therefor |
CN110478452A (en) * | 2019-10-16 | 2019-11-22 | 江西中医药大学附属医院 | A kind of Chinese medicine composition and preparation method thereof for treating gout |
-
2012
- 2012-05-22 KR KR1020120054499A patent/KR20130130580A/en not_active Application Discontinuation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104800695A (en) * | 2015-05-11 | 2015-07-29 | 广西梧州茂圣茶业有限公司 | Liupu tea-containing composition with function of reducing blood uric acid |
KR101715520B1 (en) | 2015-11-12 | 2017-03-13 | 한림대학교 산학협력단 | The pharmaceutical compositions for the treatment of gout |
WO2018079985A1 (en) | 2016-10-25 | 2018-05-03 | 엘지전자 주식회사 | Vacuum cleaner and control method therefor |
CN110478452A (en) * | 2019-10-16 | 2019-11-22 | 江西中医药大学附属医院 | A kind of Chinese medicine composition and preparation method thereof for treating gout |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101099004B1 (en) | A composition for preventing or treating a gastrointestinal disease | |
CN102302555A (en) | Chinese medicinal extract for treating urarthritis, as well as preparation method and application thereof | |
KR20110006642A (en) | Anti-arthritis and cartilage protective herbal preparations containing reduced cucurbitacin b | |
JP2009542634A (en) | Pharmaceutical composition for the prevention and treatment of inflammatory diseases comprising extract | |
CN101708241B (en) | Medicinal composition for eliminating dampness and relieving itching | |
KR20130130580A (en) | Composition for preventing or treating gout containing mixed medicinal herbs extracts and method of preparing the extracts | |
CN104706759A (en) | Health product or pharmaceutical composition capable of promoting bone or joint health, and preparation method and application thereof | |
CN1970032B (en) | Chinese medicine containing honeysuckle flower and weeping forsythia for treating cold | |
CN1616381A (en) | Process for preparing Erigeron breviscapus active component | |
CN103690582B (en) | A kind of compositions and application thereof containing dendrobium polysaccharide and atractylis concrete | |
KR101416453B1 (en) | A medicine composition for treating bronchial asthma and preparative method thereof | |
KR100601390B1 (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
KR100878436B1 (en) | Pharmaceutical composition comprising extract of lonicera japonica for prevention and treatment of digestive ulcer | |
KR100847440B1 (en) | Drug of herbal mixture for treating or preventing inflammatory diseases | |
KR20140072486A (en) | A composition comprising extracts of herbal mixture for treating or preventing chronic sinusitis or allergic rhinitis | |
CN1679698A (en) | Medicinal preparation containing notoginseng and lovge rhizome for treating cardio-cerebral blood vessel diseases and its preparing method | |
KR101085219B1 (en) | Herb extract which are effective on improvement of brain function | |
KR101119410B1 (en) | Foeniculum vulgar extracts compositions for treating or preventing inflammatory diseases | |
WO2019142062A2 (en) | Synergistic herbal composition with anti-proliferative activity | |
JP5231244B2 (en) | Mokubetsu extract useful for prevention and treatment of gastritis or gastric ulcer and momordica saponin I isolated therefrom | |
CN103623340A (en) | Chinese herbal preparation for treating gout and preparation method thereof | |
CN104095940B (en) | A kind of Chinese medicine composition for the treatment of gout | |
KR20140118322A (en) | Composition for preventing baldness and improving hair growth and method of preparing the extracts | |
KR101086037B1 (en) | Preventive and curative extracts from Sophorae Radix for respiratory organ disease | |
KR101379368B1 (en) | Composition for treating alcohol intoxication containing fructus xanthii extracts and method of preparing the extracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |